Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q4 FY23 results · Jan–Mar 2023

Aurobindo Pharma reported revenue from operations of ₹6,472.96 crore (up 11.4% from Q4 FY22) and net profit of ₹505.91 crore (down 12.2% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	6,472.96	5,809.37	+11.4%	6,407.13	+1.0%
Other income	134.91	48.88	+176.0%	92.65	+45.6%
Total income	6,607.87	5,858.25	+12.8%	6,499.78	+1.7%
Profit before share of associates & JVs and tax	735.92	597.74	+23.1%	680.70	+8.1%
Share of profit/(loss) of associates & JVs	(5.86)	(4.11)		(0.59)
Net profit for the period	505.91	576.14	−12.2%	491.01	+3.0%
Attributable to shareholders of the company	506.27	576.46	−12.2%	491.26	+3.1%
EPS, basic (₹)	8.64	9.84	−12.2%	8.38	+3.1%
Net margin (%)	7.8	9.9		7.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	3,547.44	2,887.17	+22.9%	3,432.26	+3.4%
Other income	288.17	413.37	−30.3%	78.73	+266.0%
Total income	3,835.61	3,300.54	+16.2%	3,510.99	+9.2%
Profit before tax	816.03	739.50	+10.3%	404.49	+101.7%
Net profit for the period	644.80	802.16	−19.6%	298.82	+115.8%
EPS, basic (₹)	11.00	13.69	−19.6%	5.10	+115.7%
Net margin (%)	18.2	27.8		8.7

Consolidated

Filed with BSE: 27 May 2023, 22:13 IST
Board meeting: 27 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 27 May 2023, 22:13 IST
Board meeting: 27 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE